Obermatt
See Similar Stocks →

Sangamo Therapeutics

NAQ:SGMO · US8006771062
BiotechnologySmall

360

34
Profit price13
Owner Earnings Yield1
Dividend Yield1
Price/Sales96
Price/Book72
Returns on capital8
Profit margins5
Accruals75
Owner Earnings Margin43
Sales growth77
Profit growth75
Reinvestment21
Price momentum4
Debt load1
Refinancing1
Debt Payback1
Liquidity95
Analyst ratings5
Expectations trend50
Market mood35
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sangamo Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeOTCPK
Founded1995
Employees229
Websitesangamo.com
ISINUS8006771062
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesStem Cell TherapyHematologyNeurologyPain ManagementGeneticsNeuroscienceGenetic DisorderCentral Nervous SystemBiotechnologyPharmaceuticalTherapeutics

Description

Sangamo Therapeutics, Inc. (‘Sangamo’) operates as a genomic medicine company committed to translating science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Core Neurology Programs Th…

Analysis

Middle-of-the-road

Sangamo Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
11
2026

All-time high

51

Mar 2026

All-time low

11

Jun 2026

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
—
—
—
Price/Earnings
19
—
—
—
Price/Book
72
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
62
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sangamo Therapeutics with its peers
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Achieve Life Sciences
NAQ:ACHV
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Solid Biosciences
NSQ:SLDB
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →